Yes-associated protein 1 (YAP1)
Yes-Associated Protein 1 (YAP1) is a transcriptional coactivator protein that serves as a principal effector of the Hippo signaling pathway.
Yes-Associated Protein 1 (YAP1) is a transcriptional coactivator protein that serves as a principal effector of the Hippo signaling pathway. Lacking its own DNA-binding domain, YAP1 acts by partnering with sequence-specific transcription factors—most notably the TEAD family—to switch on gene expression programs governing cell proliferation, survival, tissue growth, and regeneration. Its activity is controlled by upstream Hippo kinases, which phosphorylate YAP1 to retain it in the cytoplasm; when this restraint weakens, YAP1 translocates to the nucleus, where it can also form biomolecular condensates that concentrate transcriptional machinery and interacting partners such as JUNB and TCF12. Because it integrates mechanical cues from the extracellular matrix and cytoskeleton with biochemical signals, YAP1 is a central node in mechanotransduction.
In biomedical research, YAP1 is studied chiefly as an oncogenic and pro-fibrotic signaling protein alongside its paralog WWTR1 (TAZ). Elevated or sustained YAP1 activity is linked to tumor progression, stemness, and therapy resistance across cancers including hepatocellular carcinoma, ovarian cancer, and small cell neuroendocrine carcinoma, and it intersects with pathways such as Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB)/mTOR and MAPK signaling and with the tumor microenvironment. YAP1 also drives maladaptive tissue responses—for example, tubular cell cellular senescence and epithelial–mesenchymal transition in kidney fibrosis, and TGF-β–associated remodeling—while conversely supporting beneficial repair in wound healing and neuronal differentiation through mechanotransduction. Additional work connects YAP1 to ferroptosis regulation via axes involving Gpx4 and GLS1. These roles make YAP1 an actively pursued therapeutic target, addressed through approaches ranging from small-molecule inhibitors such as verteporfin to lipid nanoparticle–delivered siRNA that silences its expression.
Where the papers sit
12 papers from the last 6 months study Yes-associated protein 1 (YAP1) directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 observational · 8 preclinical · 3 unclassified
Themes 3 themes
-
Hippo-YAP Biology
Hippo-YAP signaling is being examined across cancer, reproductive aging, and therapeutic delivery rather than one disease. YAP1 and WWTR1 silencing with chemically optimized siRNA-LNPs represents a direct intervention, while prognostic work tests protein and genetic markers in small-cell neuroendocrine tumors. HCC studies link pathway activation to metabolic disorders, and aging-associated chromatin repression connects it to ovarian germ-cell decline. Radiotherapy-induced chemokine decoys extend treatment concepts into glioblastoma, but no single clinical direction dominates.
5 papers · 41.7%
-
YAP1-Driven Cancer Progression
YAP1 is emerging as a convergence point for metabolic, inflammatory, and redox signals that sustain solid-tumor growth. ROS-MST1-YAP activation is being therapeutically reversed by ultrasound-responsive nanodroplets, while photodynamic and photothermal treatment disrupts YAP1/β-catenin in osteosarcoma. HRH1-YAP1 feedback in pancreatic cancer and obesity-linked GABA loss with metabolic rewiring in colorectal cancer add disease-specific drivers. The field is moving toward mechanism-matched combinations and YAP1-linked response prediction, but evidence remains largely preclinical.
4 papers · 33.3%
-
Matrix-Driven YAP1 Remodeling
Matrix mechanics and injury-associated metabolism are being linked to YAP1-driven tissue remodeling. Collagen-based conductive hydrogels use mechanoelectrical signaling to promote neuronal differentiation, whereas kidney injury work targets YAP1-mediated tubular-cell senescence to limit maladaptive repair and fibrosis. In diabetic retinopathy, lactate-induced MBD2 K186 lactylation drives YAP1-dependent myofibroblast-like Müller-cell remodeling. The shared direction is to modulate YAP1 according to tissue context—enhancing regenerative differentiation while restraining fibrotic conversion.
3 papers · 25%
Papers
The 12 papers from the last 6 months that study Yes-associated protein 1 (YAP1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Hippo-YAP Biology (5)
- Age-associated chromatin repression of Hippo-Yap signaling drives oogonial stem cell decline in chicken. Functional & integrative genomics · 7 Sept 2026 PMID 42704492
- Tumorigenesis of Hepatocellular Carcinoma Related to Metabolic Disorders With a Focus on the Hippo Pathway. Applied immunohistochemistry & molecular morphology : AIMM · 22 Jul 2026 PMID 42482663
- Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1. Nucleic acid therapeutics · 22 Jul 2026 PMID 42482513
- Hijacking radiotherapy-induced chemokines with self-assembled molecular decoys for glioblastoma radio-immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 2 Jul 2026 PMID 42392408
- Comparison of protein-based and genetic prognostic markers in a large cohort of primary pulmonary and extrapulmonary small cell neuroendocrine carcinoma. Lung cancer (Amsterdam, Netherlands) · 30 May 2026 PMID 42217423
YAP1-Driven Cancer Progression (4)
- Obesity-driven microbial GABA depletion promotes metabolic rewiring and colorectal cancer progression. Nature communications · 26 Jul 2026 PMID 42503520
- Ultrasound-responsive nanodroplets activate the Hippo pathway via ROS-MST1-YAP cascade for breast cancer therapy. Ultrasonics sonochemistry · 6 Jul 2026 PMID 42407381
- A HRH1-YAP1 feedback loop drives pancreatic cancer progression and predicts therapeutic response. Oncology letters · 1 Jul 2026 PMID 42383289
- A BODIPY-based nanotheranostic suppresses osteosarcoma via dual photodynamic/photothermal action by disruption of YAP1/β-catenin Axis. Journal of photochemistry and photobiology. B, Biology · 18 Jun 2026 PMID 42314525
Matrix-Driven YAP1 Remodeling (3)
- Lactate-induced MBD2 K186 lactylation promotes YAP1-dependent myofibroblast-like remodeling of Müller cells in diabetic retinopathy. Molecular biomedicine · 5 Oct 2026 PMID 42834249
- Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 1 Jul 2026 PMID 42381472
- Bioinspired Anisotropic Collagen-Based Conductive Hydrogels Promote Neuronal Differentiation via Activation of Mechanoelectrical Signaling. ACS applied bio materials · 27 Jun 2026 PMID 42363939
By study type
Observational studies and case reports (1)
- Comparison of protein-based and genetic prognostic markers in a large cohort of primary pulmonary and extrapulmonary small cell neuroendocrine carcinoma. Lung cancer (Amsterdam, Netherlands) · 30 May 2026 PMID 42217423
Preclinical: animal, cell and lab studies (8)
- Lactate-induced MBD2 K186 lactylation promotes YAP1-dependent myofibroblast-like remodeling of Müller cells in diabetic retinopathy. Molecular biomedicine · 5 Oct 2026 PMID 42834249
- Age-associated chromatin repression of Hippo-Yap signaling drives oogonial stem cell decline in chicken. Functional & integrative genomics · 7 Sept 2026 PMID 42704492
- Obesity-driven microbial GABA depletion promotes metabolic rewiring and colorectal cancer progression. Nature communications · 26 Jul 2026 PMID 42503520
- Ultrasound-responsive nanodroplets activate the Hippo pathway via ROS-MST1-YAP cascade for breast cancer therapy. Ultrasonics sonochemistry · 6 Jul 2026 PMID 42407381
- Hijacking radiotherapy-induced chemokines with self-assembled molecular decoys for glioblastoma radio-immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 2 Jul 2026 PMID 42392408
- Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 1 Jul 2026 PMID 42381472
- Bioinspired Anisotropic Collagen-Based Conductive Hydrogels Promote Neuronal Differentiation via Activation of Mechanoelectrical Signaling. ACS applied bio materials · 27 Jun 2026 PMID 42363939
- A BODIPY-based nanotheranostic suppresses osteosarcoma via dual photodynamic/photothermal action by disruption of YAP1/β-catenin Axis. Journal of photochemistry and photobiology. B, Biology · 18 Jun 2026 PMID 42314525
Unclassified: not yet indexed with MeSH (3)
- Tumorigenesis of Hepatocellular Carcinoma Related to Metabolic Disorders With a Focus on the Hippo Pathway. Applied immunohistochemistry & molecular morphology : AIMM · 22 Jul 2026 PMID 42482663
- Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1. Nucleic acid therapeutics · 22 Jul 2026 PMID 42482513
- A HRH1-YAP1 feedback loop drives pancreatic cancer progression and predicts therapeutic response. Oncology letters · 1 Jul 2026 PMID 42383289
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-09 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.